Mark Collins

Mark A Collins, Ph.D. has spent 40 years trying to teach computers to help humans discover better drugs. Mark has held senior roles at the intersection of software; artificial intelligence; drug discovery and business in startup biotech, large pharma and tech companies; and has founded and grown several startups to successful exits. Mark is currently chief scientific officer at Undaunted Bio, a clinical-stage startup using an AI-driven reverse translation approach to repurposing drugs for neuropathic pain. Mark also helps mentor startups in the LifeX accelerator and provides technical input to the LifeX Ventures due diligence team.